UBS initiated coverage on Solventum with a new price target
$SOLV
Medical/Dental Instruments
Health Care
UBS initiated coverage of Solventum with a rating of Neutral and set a new price target of $77.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2026 | $94.00 | Outperform | Wedbush |
| 5/14/2026 | $50.00 | Buy → Neutral | UBS |
| 3/24/2026 | $60.00 | Sell | Rothschild & Co Redburn |
| 1/26/2026 | $97.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/20/2026 | $100.00 | Neutral → Outperform | Mizuho |
| 12/2/2025 | $100.00 | Neutral → Buy | BTIG Research |
| 10/1/2025 | $77.00 | Neutral | UBS |
| 9/11/2025 | $80.00 | Hold | Jefferies |
4 - Solventum Corp (0001964738) (Issuer)
EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m. EDT in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pion
ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May 13, 2026, beginning at approximately 10:00 a.m. PDT in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challeng
Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
SD - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
Wedbush initiated coverage of Solventum with a rating of Outperform and set a new price target of $94.00
UBS downgraded Solventum from Buy to Neutral and set a new price target of $50.00
Rothschild & Co Redburn initiated coverage of Solventum with a rating of Sell and set a new price target of $60.00
Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating
ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Tuesday, May 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:63
Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)
The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,
ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to